d, that third
parties on whom we depend will perform as anticipated, or that our products
or product candidates will not be unfavorably compared to competitive
products that may be regarded as safer, more effective, easier to use or
less expensive. Actual results may also differ substantially from those
described in or contemplated by this press release due to risks and
uncertainties that exist in our operations and business environment,
including, without limitation, risks and uncertainties that are inherent in
the development of complex biologics and therapeutic hypothermia devices
and in the conduct of human clinical trials, including the timing, costs
and outcomes of such trials, our ability to obtain necessary funding,
regulatory approvals and expected qualifications, our ability to
successfully accelerate the commercialization of our therapeutic
hypothermia devices and launch new devices within the timeframes
contemplated, our dependence upon proprietary technology, our history of
operating losses and accumulated deficits, our reliance on collaborative
relationships and critical personnel, and current and future competition,
as well as other risks described from time to time in filings we make with
the Securities and Exchange Commission. We undertake no obligation to
release publicly the results of any revisions to these forward-looking
statements to reflect events or circumstances arising after the date
hereof.
Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.
For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.
Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium
Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM)
are trademarks of Tissue Repair Company. InnerCool Therapies(R), InnerCool(R), Celsius Control System(R),
RapidBlue(TM
'/>"/>
SOURCE Cardium Therapeutics Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System2.
ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels3.
Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification4.
Cardium Announces Follow-On Direct Investment by Institutional Investor5.
Cardium Selected for Inclusion in Russell Microcap Index6.
Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems7.
Cardium Launches New AWARE Clinical Study Website8.
Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability9.
Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 200810.
Cardium Reports on First Quarter 2008 Highlights and Financial Results11.
Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board